Company intelligence / Profile preview

Apieron

Burlingame, CA, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Apeiron Therapeutics is advancing a robust pipeline of targeted cancer treatments using AI-driven drug discovery. The company recently presented preclinical data on its PRMT5 inhibitor GTA182 at AACR 2025. No late-stage or commercialized products are reported yet; the focus remains on early clinical development and preclinical research for novel oncology therapies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Viva Biotech/Viva BioInnovator

Beyond the preview

Go deeper on Apieron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apieron.

Explore the full profile